Torrent Pharmaceuticals' Q3 FY 2025-26 Quarterly Results
- 14 Feb 2026
Result Summary
- Torrent Pharmaceuticals Ltd reported a 0.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 15.8%.
- Its expenses for the quarter were down by 0.2% QoQ and up 14.6% YoY.
- The net profit increased 7.4% QoQ and increased 26.2% YoY.
- The earnings per share (EPS) of Torrent Pharmaceuticals Ltd stood at 18.77 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 3290.00 | 3275.00 | 2842.00 | 0.5% | 15.8% |
Total Expenses | 2466.00 | 2471.00 | 2151.00 | -0.2% | 14.6% |
Profit Before Tax | 814.00 | 791.00 | 691.00 | 2.9% | 17.8% |
Tax | 179.00 | 200.00 | 188.00 | -10.5% | -4.8% |
Profit After Tax | 635.00 | 591.00 | 503.00 | 7.4% | 26.2% |
Earnings Per Share | 18.77 | 17.45 | 14.88 | 7.6% | 26.1% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Torrent Pharmaceuticals Ltd is a prominent player in the pharmaceutical industry, known for manufacturing and marketing a broad range of pharmaceutical products. The company primarily operates in the areas of cardiovascular, central nervous system, gastroenterology, diabetology, anti-infective, and pain management. Torrent Pharmaceuticals has a significant presence in both domestic and international markets, with a focus on innovation and quality. The company has built a strong reputation over the years by maintaining a robust pipeline of new drug developments and consistently expanding its product portfolio. Recent developments, if any, are not available in the provided data.
Revenue
In the third quarter of the fiscal year 2026 (Q3FY26), Torrent Pharmaceuticals reported a total income of ₹3290 crores. This marks a slight quarter-over-quarter (QoQ) increase of 0.5% compared to ₹3275 crores in the previous quarter (Q2FY26). On a year-over-year (YoY) basis, the total income saw a significant rise of 15.8% from ₹2842 crores in the same quarter of the previous fiscal year (Q3FY25). This growth reflects the company's ability to generate higher revenue compared to both the preceding quarter and the corresponding quarter of the previous year.
Profitability
The company demonstrated strong profitability in Q3FY26, with a profit before tax (PBT) of ₹814 crores, which is a 2.9% increase from the ₹791 crores reported in Q2FY26. Year-over-year, the PBT rose by 17.8% from ₹691 crores in Q3FY25. Torrent Pharmaceuticals' tax expenses for Q3FY26 were ₹179 crores, showing a decrease of 10.5% QoQ and a slight decrease of 4.8% YoY. Consequently, the profit after tax (PAT) for Q3FY26 was ₹635 crores, an increase of 7.4% QoQ from ₹591 crores and 26.2% YoY from ₹503 crores. This robust growth in PAT highlights the company's effective cost management and operational efficiency.
Operating Metrics
The earnings per share (EPS) for Torrent Pharmaceuticals in Q3FY26 stood at ₹18.77, reflecting a QoQ increase of 7.6% from ₹17.45 in Q2FY26, and a YoY increase of 26.1% from ₹14.88 in Q3FY25. This upward trend in EPS indicates an improvement in the company's earnings performance relative to the number of shares outstanding. Total expenses for the quarter were ₹2466 crores, a marginal decrease of 0.2% QoQ from ₹2471 crores in Q2FY26, while showing a 14.6% increase YoY from ₹2151 crores in Q3FY25. The data indicates that while total expenses have grown compared to the same quarter last year, they have slightly decreased from the previous quarter.